These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 30340144)

  • 21. Opioid agonist therapy engagement and crystal methamphetamine use: The impact of unregulated opioid use in Vancouver, Canada.
    Cui Z; Bach P; Ti L; Hayashi K; Morgan J; Milloy MJ; Kerr T
    Int J Drug Policy; 2022 Dec; 110():103879. PubMed ID: 36265327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012-2018.
    Krebs E; Homayra F; Min JE; MacDonald S; Gold L; Carter C; Nosyk B
    Drug Alcohol Depend; 2021 Aug; 225():108799. PubMed ID: 34087747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with methadone maintenance therapy discontinuation among people who inject drugs.
    Lo A; Kerr T; Hayashi K; Milloy MJ; Nosova E; Liu Y; Fairbairn N
    J Subst Abuse Treat; 2018 Nov; 94():41-46. PubMed ID: 30243416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Opioid agonist therapy switching among individuals with prescription-type opioid use disorder: Secondary analysis of a pragmatic randomized trial.
    Mocanu V; Bozinoff N; Wood E; Jutras-Aswad D; Le Foll B; Lim R; Cheol Choi J; Yin Mok W; Eugenia Socias M;
    Drug Alcohol Depend; 2023 Jul; 248():109932. PubMed ID: 37224674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17.
    Larney S; Jones NR; Hickman M; Nielsen S; Ali R; Degenhardt L
    Addiction; 2023 Aug; 118(8):1527-1539. PubMed ID: 36843415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-incarceration outcomes for individuals who continued methadone treatment while in Connecticut jails, 2014-2018.
    Haas A; Viera A; Doernberg M; Barbour R; Tong G; Grau LE; Heimer R
    Drug Alcohol Depend; 2021 Oct; 227():108937. PubMed ID: 34371235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L; Iversen J; Wand H; Maher L
    Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Punitive discontinuation of opioid agonist therapy during incarceration.
    Marmel A; Bozinoff N
    Int J Prison Health; 2020 Aug; 16(4):337-342. PubMed ID: 33634666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interest in using buprenorphine-naloxone among a prospective cohort of street-involved young people in Vancouver, Canada.
    Pilarinos A; Bingham B; Kwa Y; Joe R; Grant C; Fast D; Buxton JA; DeBeck K
    J Subst Use Addict Treat; 2023 May; 148():209005. PubMed ID: 36921770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons.
    Treitler PC; Enich M; Reeves D; Crystal S
    Subst Abus; 2022; 43(1):964-971. PubMed ID: 35420973
    [No Abstract]   [Full Text] [Related]  

  • 31. Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration.
    Cherian T; Lim S; Katyal M; Goldfeld KS; McDonald R; Wiewel E; Khan M; Krawczyk N; Braunstein S; Murphy SM; Jalali A; Jeng PJ; Rosner Z; MacDonald R; Lee JD
    Drug Alcohol Depend; 2024 Jun; 259():111274. PubMed ID: 38643529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing Canadian and United States opioid agonist therapy policies.
    Priest KC; Gorfinkel L; Klimas J; Jones AA; Fairbairn N; McCarty D
    Int J Drug Policy; 2019 Dec; 74():257-265. PubMed ID: 30765118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of the implementation of medication for opioid use disorder and COVID-19 in a statewide correctional system on treatment engagement, postrelease continuation of care, and overdose.
    Klemperer EM; Wreschnig L; Crocker A; King-Mohr J; Ramniceanu A; Brooklyn JR; Peck KR; Rawson RA; Evans EA
    J Subst Use Addict Treat; 2023 Sep; 152():209103. PubMed ID: 37311520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cannabis use is associated with reduced risk of exposure to fentanyl among people on opioid agonist therapy during a community-wide overdose crisis.
    Socías ME; Choi J; Lake S; Wood E; Valleriani J; Hayashi K; Kerr T; Milloy MJ
    Drug Alcohol Depend; 2021 Feb; 219():108420. PubMed ID: 33342591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey.
    Kouyoumdjian FG; Patel A; To MJ; Kiefer L; Regenstreif L
    PLoS One; 2018; 13(2):e0192431. PubMed ID: 29447177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
    Brezel ER; Powell T; Fox AD
    Subst Abus; 2020; 41(2):150-154. PubMed ID: 31800376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial.
    Bahji A; Bastien G; Bach P; Choi J; Le Foll B; Lim R; Jutras-Aswad D; Socias ME
    Can J Psychiatry; 2024 Mar; 69(3):172-182. PubMed ID: 37697811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder.
    Schiff DM; Nielsen TC; Hoeppner BB; Terplan M; Hadland SE; Bernson D; Greenfield SF; Bernstein J; Bharel M; Reddy J; Taveras EM; Kelly JF; Wilens TE
    Am J Obstet Gynecol; 2021 Oct; 225(4):424.e1-424.e12. PubMed ID: 33845029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determinants of selection into buprenorphine/naloxone among people initiating opioid agonist treatment in British Columbia.
    Homayra F; Hongdilokkul N; Piske M; Pearce LA; Zhou H; Min JE; Krebs E; Nosyk B
    Drug Alcohol Depend; 2020 Feb; 207():107798. PubMed ID: 31927163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with patient perceived suboptimal dosing of in-hospital opioid agonist therapy among people who use illicit drugs in Vancouver, Canada.
    El-Akkad SE; Nolan S; Hayashi K; Dong H; Milloy MJ; Debeck K; Ti L
    J Addict Dis; 2023; 41(3):204-212. PubMed ID: 35727118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.